On October 18, 2012, the CHMP adopted a few negative opinions, recommending the refusal of the marketing authorization for the medicinal products Acrescent and Balaxur (memanthine hdrochloride / donepezil hydrochloride) intented for the treatment of moderate to severe Alzheimer’s disease, and Qsiva (phentermine/topiramate) intented for the treatment of obesity.
The companies that applied for these authorizations may request re-examniation of the opinion with 15 days of receipt of notification of this negative opinion!
Posted on the EMA website on 18 October 2012